Revvity (RVTY) to Release Quarterly Earnings on Monday

Revvity (NYSE:RVTY) will be issuing its quarterly earnings data before the market opens on Monday, April 29th. Analysts expect the company to announce earnings of $0.94 per share for the quarter. Revvity has set its FY 2024 guidance at 4.550-4.750 EPS and its FY24 guidance at $4.55-$4.75 EPS.Parties interested in listening to the company’s conference call can do so using this link.

Revvity (NYSE:RVTY) last issued its earnings results on Thursday, February 1st. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.15 by $0.10. Revvity had a return on equity of 7.41% and a net margin of 25.20%. The business had revenue of $695.90 million during the quarter. On average, analysts expect Revvity to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Revvity Trading Down 0.6 %

Shares of RVTY opened at $101.51 on Friday. Revvity has a 1 year low of $79.50 and a 1 year high of $132.54. The company has a current ratio of 2.07, a quick ratio of 1.77 and a debt-to-equity ratio of 0.40. The stock has a 50 day simple moving average of $104.66 and a 200-day simple moving average of $101.40. The stock has a market cap of $12.54 billion, a PE ratio of 18.46, a PEG ratio of 2.66 and a beta of 1.09.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 9th. Stockholders of record on Friday, July 19th will be issued a $0.07 dividend. The ex-dividend date is Friday, July 19th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.28%. Revvity’s payout ratio is presently 5.09%.

Analysts Set New Price Targets

RVTY has been the subject of a number of recent analyst reports. Raymond James raised their price target on Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. KeyCorp raised their price target on Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a report on Friday, February 2nd. Barclays raised their price target on Revvity from $92.00 to $105.00 and gave the company an “equal weight” rating in a report on Thursday, January 25th. Stifel Nicolaus raised their price target on Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a report on Friday, February 2nd. Finally, UBS Group cut Revvity from a “buy” rating to a “neutral” rating and raised their price target for the company from $105.00 to $125.00 in a report on Tuesday, January 16th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.91.

Insiders Place Their Bets

In other news, insider Prahlad R. Singh sold 21,217 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $104.28, for a total value of $2,212,508.76. Following the sale, the insider now directly owns 92,801 shares in the company, valued at $9,677,288.28. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.60% of the company’s stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.